A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 Years With Pulmonary Arterial Hypertension
Latest Information Update: 12 Jan 2025
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms SALTO
- Sponsors Actelion Pharmaceuticals; Janssen Research & Development
Most Recent Events
- 04 Dec 2024 Planned End Date changed from 10 Jan 2028 to 1 Oct 2027.
- 19 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.
- 19 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.